A head-to-head comparison of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG PET/CT in the diagnosis of lung cancer
Purpose This study aimed to compare the diagnostic value of [ 68 Ga]Ga-DOTA-FGFR1 and [ 18 F]FDG PET/CT in the evaluation of lung cancer patients. Methods A prospective study was conducted between March 2023 and July 2023. Patients with high clinical suspicion of lung cancer were recruited. Each par...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2025-02, Vol.52 (3), p.979-992 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
This study aimed to compare the diagnostic value of [
68
Ga]Ga-DOTA-FGFR1 and [
18
F]FDG PET/CT in the evaluation of lung cancer patients.
Methods
A prospective study was conducted between March 2023 and July 2023. Patients with high clinical suspicion of lung cancer were recruited. Each participant underwent PET/CT scanning using [
68
Ga]Ga-DOTA-FGFR1 and [
18
F]FDG within 6 days. Histopathology and clinical follow-up results serve as reference criteria for final diagnosis. We used a paired samples t-test or a Wilcoxon signed-rank test to compare the uptake of [
68
Ga]Ga-DOTA-FGFR1 and [
18
F]FDG. The diagnostic performance between the two tracers was compared using the McNemar χ² test.
Results
A total of 101 participants were included (mean age 63.267 ± 9.344 [range 39–86 years]). In benign lung lesions, [
68
Ga]Ga-DOTA-FGFR1 had lower TBR and SUVmax than [
18
F]FDG (2.924 vs. 5.705,
P
|
---|---|
ISSN: | 1619-7070 1619-7089 |
DOI: | 10.1007/s00259-024-06976-4 |